Replies to post #140772 on Biotech Values

[biomaven0]

>Promacta

I'm still hard pressed to see this as a >$1b drug, as some analysts are projecting. But LGND still does well at half that once all the captisol royalties kick in at full strength.

Here's a comprehensive analysis of LGND, albeit too optimistic in the out years by my thinking:

http://www.griffinsecurities.com/upload/reports/Griffin_LGND_Initiation_Report_22Nov11.pdf

Dinaciclib (partnered by Merck) in triple-negative breast cancer is something to watch I think.

Peter